Salamoon et al., 2013 - Google Patents
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL)Salamoon et al., 2013
- Document ID
- 6985710104447881619
- Author
- Salamoon M
- Hussein T
- Kenj M
- Bachour M
- Publication year
- Publication venue
- Medical Oncology
External Links
Snippet
Abstract Treatment of primary central nervous system lymphoma (PCNSL) associates with low response rates and poor survival using conventional radio and chemotherapy. Due to its favorable toxicity profile, temozolomide has emerged as a new option for treatment of …
- 206010007953 Central nervous system lymphoma 0 title abstract description 42
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Phillips et al. | A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma | |
| Bromberg et al. | Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study | |
| Schaff et al. | Primary central nervous system lymphoma | |
| Hoang-Xuan et al. | Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology | |
| Fowler et al. | Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study | |
| Morris et al. | Therapeutic challenges in primary CNS lymphoma | |
| Ferreri et al. | High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial | |
| Omuro et al. | Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly | |
| Jahnke et al. | International study on low‐grade primary central nervous system lymphoma | |
| Adhikari et al. | A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome | |
| Kim et al. | CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas | |
| Choi et al. | Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation | |
| Wu et al. | Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study | |
| Salamoon et al. | High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL) | |
| Doucet et al. | Primary central nervous system lymphoma | |
| Correia et al. | Central nervous system lymphoma: approach to diagnosis and treatment | |
| Nayak et al. | Recent advances in treatment of primary central nervous system lymphoma | |
| Roth et al. | Treatment of primary CNS lymphoma | |
| Biasoli et al. | Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry | |
| Rueda Domínguez et al. | SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma | |
| Tessoulin et al. | Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/− R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas | |
| Makino et al. | Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience | |
| Ly et al. | Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience | |
| Zhao et al. | Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma | |
| Han et al. | Primary central nervous system lymphoma |